Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Kevin Kim

Hematology | Oncology
2100 Webster St, 
San Francisco, CA 
Offers Telehealth

Experienced in WT1-Related Wilms Tumor Syndromes
2100 Webster St, 
San Francisco, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kevin Kim is a Hematologist and an Oncologist in San Francisco, California. Dr. Kim is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Melanoma, Metastatic Uveal Melanoma, Melanoma of the Eye, and Uveal Melanoma.

His clinical research consists of co-authoring 130 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in TX
Hospital Affiliations
California Pacific Medical Center - Mission Bernal
California Pacific Medical Center- Van Ness Campus
Novato Community Hospital
Sutter Davis Hospital
California Pacific Medical Ctr-Davies Campus Hosp
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Moda Health
  • EPO
  • PPO
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
Sutter Health
  • HMO
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

2100 Webster St, San Francisco, CA 94115

Additional Areas of Focus

Dr. Kim has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


9 Clinical Trials

A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Enrollment Status: Terminated
Publish Date: September 18, 2025
Intervention Type: Biological, Drug, Other
Study Drugs: Dabrafenib, Trametinib, Spartalizumab (PDR001)
Study Phase: Phase 3
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Biological, Drug
Study Drugs: IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab
Study Phase: Phase 2
A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: July 03, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies
An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies
Enrollment Status: Completed
Publish Date: May 11, 2025
Intervention Type: Drug
Study Drugs: SEA-CD40, Pembrolizumab, Pemetrexed, Carboplatin
Study Phase: Phase 2
A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma
A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma
Enrollment Status: Completed
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: IMCgp100
Study Phase: Phase 1/Phase 2
Blood and Tumor Sample Collection From Patients With Malignant Melanoma for Long Term Storage
Blood and Tumor Sample Collection From Patients With Malignant Melanoma for Long Term Storage
Enrollment Status: Terminated
Publish Date: September 02, 2022
Intervention Type: Procedure
A Feasibility Study of Sequential Hepatic Internal Radiation and Systemic Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastatic to Liver.
A Feasibility Study of Sequential Hepatic Internal Radiation and Systemic Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastatic to Liver.
Enrollment Status: Unknown
Publish Date: April 19, 2021
Intervention Type: Drug, Device
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
A Phase 1, Open-Label Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of Intradermally Administered ID-LV305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
A Phase 1, Open-Label Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of Intradermally Administered ID-LV305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Enrollment Status: Completed
Publish Date: March 06, 2019
Intervention Type: Biological
Study Phase: Phase 1
A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma
A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma
Enrollment Status: Withdrawn
Publish Date: February 01, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

130 Total Publications

Phase II Study of Niraparib in Patients With Advanced Melanoma With Homologous Recombination Pathway Gene Mutations.
Phase II Study of Niraparib in Patients With Advanced Melanoma With Homologous Recombination Pathway Gene Mutations.
Journal: JCO precision oncology
Published: May 15, 2025
View All 130 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Sandhya S. Srinivas
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Sandhya S. Srinivas
Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (28.4 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sandhya Srinivas is an Oncologist in Stanford, California. Dr. Srinivas is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Renal Cell Carcinoma (RCC), Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, Chromophobe Renal Cell Carcinoma, and Endoscopy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Alice C. Fan
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Alice C. Fan
Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (28.4 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alice Fan is an Oncologist in Stanford, California. Dr. Fan is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Renal Cell Carcinoma (RCC), Upper Tract Urothelial Carcinoma (UTUC), WT1-Related Wilms Tumor Syndromes, and Clear Cell Sarcoma.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Arpita K. Desai
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Arpita K. Desai
Hematology Oncology | Hematology | Oncology

Ucsf Medical Group Business Services

400 Parnassus Ave, 
San Francisco, CA 
 (2.3 miles away)
415-476-1000
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Arpita Desai is a Hematologist Oncology specialist and a Hematologist in San Francisco, California. Dr. Desai has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Renal Cell Carcinoma (RCC), Familial Wilms Tumor 2, Wilms Tumor, and WT1-Related Wilms Tumor Syndromes.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kim's expertise for a condition
ConditionClose
  • Elite
  • Melanoma
    Dr. Kim is
    Elite
    . Learn about Melanoma.
    See more Melanoma experts
  • Distinguished
  • Melanoma of the Eye
    Dr. Kim is
    Distinguished
    . Learn about Melanoma of the Eye.
    See more Melanoma of the Eye experts
  • Metastatic Uveal Melanoma
    Dr. Kim is
    Distinguished
    . Learn about Metastatic Uveal Melanoma.
    See more Metastatic Uveal Melanoma experts
  • Uveal Melanoma
    Dr. Kim is
    Distinguished
    . Learn about Uveal Melanoma.
    See more Uveal Melanoma experts
  • Advanced
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. Kim is
    Advanced
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
  • EGFR Positive Lung Cancer
    Dr. Kim is
    Advanced
    . Learn about EGFR Positive Lung Cancer.
    See more EGFR Positive Lung Cancer experts
  • Large-Cell Lung Carcinoma
    Dr. Kim is
    Advanced
    . Learn about Large-Cell Lung Carcinoma.
    See more Large-Cell Lung Carcinoma experts
  • Lung Adenocarcinoma
    Dr. Kim is
    Advanced
    . Learn about Lung Adenocarcinoma.
    See more Lung Adenocarcinoma experts
  • Lung Cancer
    Dr. Kim is
    Advanced
    . Learn about Lung Cancer.
    See more Lung Cancer experts
  • Merkel Cell Carcinoma
    Dr. Kim is
    Advanced
    . Learn about Merkel Cell Carcinoma.
    See more Merkel Cell Carcinoma experts
View All 13 Advanced Conditions
  • Experienced
  • Adult Soft Tissue Sarcoma
    Dr. Kim is
    Experienced
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Agranulocytosis
    Dr. Kim is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Alveolar Soft Part Sarcoma
    Dr. Kim is
    Experienced
    . Learn about Alveolar Soft Part Sarcoma.
    See more Alveolar Soft Part Sarcoma experts
  • Anal Cancer
    Dr. Kim is
    Experienced
    . Learn about Anal Cancer.
    See more Anal Cancer experts
  • Angiosarcoma
    Dr. Kim is
    Experienced
    . Learn about Angiosarcoma.
    See more Angiosarcoma experts
  • Aplastic Anemia
    Dr. Kim is
    Experienced
    . Learn about Aplastic Anemia.
    See more Aplastic Anemia experts
View All 45 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved